Novo Nordisk Surges 24.9% in a Month as AI-Driven Restructuring Revalues the Stock
Novo Nordisk shares climbed 24.9% over the past month after the company licensed its Parkinson's cell therapy to Cellular Intelligence and shut its internal unit. The move signals a broader pharma playbook: offload early-stage biology risk onto AI-native partners and capture upside through licensing deals. FDA Fast Track designation for the Parkinson's program removed a key regulatory overhang, amplifying investor confidence.
Salvado•